Theranostics represents one of the most significant shifts in modern oncology. The term combines "therapeutics" and "diagnostics," describing an approach in which a diagnostic test identifies whether a patient is likely to benefit from a specific therapy, and that same molecular target is then used to deliver treatment. In the UK, theranostics is moving from specialist centres into mainstream cancer care, particularly for prostate cancer, neuroendocrine tumours, and thyroid cancer. The implications for patients, clinicians, and the healthcare system are profound.

The most established theranostic pair in the UK is PSMA PET imaging combined with lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer. Patients undergo a PSMA PET scan to confirm that their tumours express the target; if uptake is sufficient, they may be eligible for radioligand therapy using the same targeting molecule. This "see it, treat it" approach has demonstrated improved survival and quality of life in clinical trials. Similar principles apply to neuroendocrine tumours using somatostatin receptor imaging and peptide receptor radionuclide therapy. According to analysis of the UK Theranostics Market, growth is being driven by rising cancer incidence, expanding clinical evidence, and investment in nuclear medicine infrastructure.

For patients, theranostics offers a personalised approach that can identify effective treatments while avoiding ineffective ones. For clinicians, it provides a framework for precision oncology. For the NHS, it presents both opportunity and challenge, requiring investment in PET scanners, radiopharmacy facilities, and specialist workforce. Challenges include capacity constraints, reimbursement pathways, and equitable access across regions.

The UK has several centres of excellence in theranostics, including specialist cancer centres and university hospitals. Initiatives such as the NHS England proton beam therapy programme and investment in radiopharmaceutical production are laying the groundwork for broader adoption. As evidence accumulates and regulatory pathways mature, theranostics is likely to expand into additional cancer types, including breast, lung, and paediatric malignancies.

For stakeholders across the healthcare ecosystem, theranostics represents a paradigm shift. It moves oncology from a trial-and-error approach to one guided by molecular imaging and targeted therapy. In the UK, this shift is well underway, and the market is positioned for sustained growth as technology, evidence, and infrastructure continue to advance.

People Also Ask

What is theranostics?
It is an approach that combines diagnostics and therapeutics, using a molecular target to both identify patients likely to benefit from a therapy and deliver that therapy.

Which cancers are treated with theranostics in the UK?
Prostate cancer, neuroendocrine tumours, and thyroid cancer are the most established applications, with research expanding into other cancers.

Tags: #Theranostics #PrecisionOncology #UKHealthcare #NuclearMedicine #CancerTreatment #PatientCare